

Tematica concursului de admitere la doctorat, anul univ. 2026-2027

Conducător de doctorat: Prof. Dr. Habil. Mira Florea

Tematica 1

1. Prevalența și particularitățile bolii hepatice steatozice asociată cu disfuncția metabolică (MASLD) la indivizii obezi și non-obezi.
2. MASLD -afectare multisistemică: hepatică, cardiovasculară, renală.
3. Complicațiile hepatice ale MASLD.
4. Complicațiile extrahepatice ale MASLD.
5. Cancerelor asociate MASLD.

Bibliografie:

1. Metabolic Dysfunction-Associated Steatotic Liver Disease- Prevalence, research insights and future directions. Editors: Nahum Mendez-Sanchez, Xingshun Qi. Springer Nature Singapore Pte Ltd. 2024. eBook ISBN 978-981-97-9519-2.
2. Essentials of Non-Alcoholic Fatty Liver Disease. Complications and Extrahepatic Manifestations. Editors: Anca Trifan, Carol Stanciu, Cristina Muzica. Springer Nature Switzerland AG 2023. <https://doi.org/10.1007/978-3-031-33548-8>.
3. NAFLD in lean individuals. Donghee Kim and Vincent Wai-Sun Wong. In: Naim Alkhouri, Stephen A. Harrison. Need-to-Know NAFLD. The Complete Guide to Nonalcoholic Fatty Liver Disease, CRC Press, 2023. ISBN 9781032479484. <https://doi.org/10.1201/9781003386698>.
4. MASLD/MASH. Andreas Geier, Elke Roeb. Chapter 9 In: Hepatology. A clinical textbook. 11th edition 2024-2025. Edited by Heiner Wedemeyer, Stefan Mauss, Thomas Berg, Verena Keitel, Jürgen Rockstroh, and Christoph Sarrazin. <https://www.hepatologytextbook.com>.
5. MASLD as a Multisystemic Disease. Chantal Jacqueline Córdova-Gallardo, Andres Manuel Vargas-Beltran. In: Nahum Mendez-Sanchez, Xingshun Qi. Metabolic Dysfunction-Associated Steatotic Liver Disease- Prevalence, research insights and future directions. Springer Nature Singapore Pte Ltd. 2024. eBook ISBN 978-981-97-9519-2.
6. MASLD and Hepatic/Extrahepatic Cancers: Understanding the Complex Relationship. Jan Best, Bernd Schnabl, Ali Canbay. In: Nahum Mendez-Sanchez, Xingshun Qi. Metabolic Dysfunction-Associated Steatotic Liver Disease- Prevalence, research insights and future directions. Springer Nature Singapore Pte Ltd. 2024. eBook ISBN 978-981-97-9519-2.
7. Steatotic Liver Disease. In: Li, H., Zhang, X. (eds) Practical Liver Pathology. Practical Anatomic Pathology. Toro, P., Allende, D.S. 2025. Springer, Cham. https://doi.org/10.1007/978-3-031-97506-6_13.
8. Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease. Sharma, A., Barb, D. In: Mechanick, J.I., Kushner, R.F. (eds) Lifestyle Medicine. Springer, Cham. 2025. https://doi.org/10.1007/978-3-031-82888-1_10.

Tematica 2

1. Modificări structurale și funcționale multimodale (analiza multi-omică, microbiom intestinal și imagistică prin rezonanță magnetică funcțională) la persoanele cu obezitate tratate cu agoniști ai receptorului GLP-1: studiu transversal și longitudinal

Bibliografie:

1. Maretty L, Gill D, Simonsen L, Soh K, Zagkos L, Galanakis M, Sibbesen J, Iglesias MT, Secher A, Valkenborg D, Purnell JQ, Knudsen LB, Tahrani AA, Geybels M. Proteomic changes upon treatment with semaglutide in individuals with obesity. *Nat Med*. 2025 Jan;31(1):267-277. doi: 10.1038/s41591-024-03355-2.
2. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. *Nat Med*. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20. Erratum in: *Nat Med*. 2025 Mar;31(3):1038. doi: 10.1038/s41591-025-03542-9.
3. Chakaroun RM, Pradhan M, Björnson E, Arvidsson D, Fridolfsson J, Gummesson A, Schoeler M, Mitteregger M, Smith GJ, Larsson I, Börjesson M, Blüher M, Uhlén M, Stumvoll M, Bergström G, Tremaroli V, Bäckhed F. Multi-omic definition of metabolic obesity through adipose tissue-microbiome interactions. *Nat Med*. 2026 Jan;32(1):113-125. doi: 10.1038/s41591-025-04009-7.
4. Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. *N Engl J Med*. 2026 Apr 2;394(13):1313-1324. doi: 10.1056/NEJMra2500106.